Corbin van de Wege, MD
Family Medicine · Springfield, MONPI 1174713564
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $831, 4.4 times the $189 reported in 2019.
Across 176 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$437
- AbbVie$402
- Abbott$299
- Pfizer$282
- AstraZeneca$193
- Lilly USA, LLC$161
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,97499%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $437 |
| AbbVie(2 entities) | 23 | $402 |
| Abbott | 15 | $299 |
| Pfizer | 21 | $282 |
| AstraZeneca | 12 | $193 |
| Lilly USA, LLC | 9 | $161 |
| GSK | 10 | $152 |
| Boehringer Ingelheim | 7 | $118 |
| Globus Medical | 3 | $92 |
| Exact Sciences | 5 | $86 |
| Daiichi Sankyo Inc. | 4 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $78 |
| Amgen | 5 | $76 |
| E.r. Squibb & Sons, L.L.C. | 5 | $73 |
| Sanofi-aventis U.S. LLC | 5 | $63 |
| Axsome Therapeutics, Inc. | 2 | $50 |
| Eisai Inc. | 3 | $44 |
| Astellas Pharma US Inc | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 3 | $40 |
| Radius Health, Inc. | 1 | $28 |
| Bayer | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Scynexis, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Agios Pharmaceuticals, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
How this compares
$3,006 in reported general payments places this provider in the 80th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 161 | $154,566 |
| EnbrelEtanercept | 13 | $95,773 |
| TrulicityDulaglutide | 60 | $77,994 |
| OzempicSemaglutide | 68 | $76,753 |
| XareltoRivaroxaban | 53 | $49,664 |
| JardianceEmpagliflozin | 34 | $25,982 |
| MounjaroTirzepatide | 21 | $23,632 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $23,627 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 12 | $18,225 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $16,547 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $15,166 |
| MyrbetriqMirabegron | 24 | $13,442 |
| FarxigaDapagliflozin Propanediol | 16 | $12,358 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 52 | $11,357 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 27 | $7,841 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $282 | $162,407188 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $161 | $101,62681 claims |
| AmgenEnbrel | $76 | $95,77313 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $437 | $94,97780 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Shingrix, Breo Ellipta | $152 | $55,728114 claims |
| Johnson & JohnsonXarelto | $12 | $49,66453 claims |
| Boehringer IngelheimJardiance | $118 | $25,98234 claims |
| AstraZenecaFarxiga, Symbicort | $193 | $16,94829 claims |
| Astellas Pharma US IncMyrbetriq | $41 | $13,44224 claims |
| AbbVieSynthroid | $402 | $1,48521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Springfield
- Stephen AdamsSpringfield$636K
- Roger CadySpringfield$175K
- Don BrockmanSpringfield$31K
- James van RiessenSpringfield$25K
- Justin PuckettKirksville$568K
- Matthew BeckerditeOfallon$225K
- James LasalleExcelsior Springs$130K
- Matthew TiefenbrunnSullivan$105K
- Ayobami OduwoleGrandview$92K
- Michael DonovanSaint Louis$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.